Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies
Open Access
- 29 September 2015
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 6 (6), 328-338
- https://doi.org/10.1177/2040622315608647
Abstract
Spondyloarthritis represents a heterogeneous group of articular inflammatory diseases that share common genetic, clinical and radiological features. The therapy target of spondyloarthritis relies mainly in improving patients’ quality of life, controlling articular inflammation, preventing the structural joints damage and preserving the functional abilities, autonomy and social participation of patients. Among these, traditional disease-modifying antirheumatic drugs have been demonstrated to be effective in the management of peripheral arthritis; moreover, in the last decade, biological therapies have improved the approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α inhibitors are currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs has failed. The aim of this review is to summarize the current experience and evidence about the pharmacological approach in spondyloarthritis patients.Keywords
This publication has 104 references indexed in Scilit:
- Enteropathic Spondyloarthritis: From Diagnosis to TreatmentClinical and Developmental Immunology, 2013
- Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Annals Of The Rheumatic Diseases, 2012
- A randomized placebo-controlled trial of methotrexate in psoriatic arthritisRheumatology, 2012
- Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitisAnnals Of The Rheumatic Diseases, 2011
- 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAnnals Of The Rheumatic Diseases, 2011
- The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot studyClinical Rheumatology, 2011
- Treatment recommendations for psoriatic arthritisAnnals Of The Rheumatic Diseases, 2008
- No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trialAnnals Of The Rheumatic Diseases, 2007
- Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trialAnnals Of The Rheumatic Diseases, 2006
- Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective studyAnnals Of The Rheumatic Diseases, 2006